1
|
Balkwill F and Mantovani A: Inflammation
and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
2
|
Aggarwal BB, Shishodia S, Sandur SK, et
al: Inflammation and cancer: how hot is the link? Biochem
Pharmacol. 72:1605–1621. 2006. View Article : Google Scholar : PubMed/NCBI
|
3
|
Grange JM, Krone B and Mastrangelo G:
Infection, inflammation and cancer. Int J Cancer. 128:2240–2241.
2011. View Article : Google Scholar : PubMed/NCBI
|
4
|
Mantovani A and Pierotti MA: Cancer and
inflammation: a complex relationship. Cancer Lett. 267:180–181.
2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Eiró N and Vizoso FJ: Inflammation and
cancer. World J Gastrointest Surg. 4:62–72. 2012.
|
6
|
Whiteside TL: The tumor microenvironment
and its role in promoting tumor growth. Oncogene. 27:5904–5912.
2008. View Article : Google Scholar : PubMed/NCBI
|
7
|
Tan TT and Coussens LM: Humoral immunity,
inflammation and cancer. Curr Opin Immunol. 19:209–216. 2007.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Arias JI, Aller MA and Arias J: Cancer
cell: using inflammation to invade the host. Mol Cancer. 6:292007.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Aggarwal BB and Gehlot P: Inflammation and
cancer: how friendly is the relationship for cancer patients? Curr
Opin Pharmacol. 9:351–369. 2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Moore MM, Chua W, Charles KA and Clarke
SJ: Inflammation and cancer: causes and consequences. Clin
Pharmacol Ther. 87:504–508. 2010. View Article : Google Scholar : PubMed/NCBI
|
11
|
Alexandrescu DT, Riordan NH, Ichim ET, et
al: On the missing link between inflammation and cancer. Dermatol
Online J. 17:102011.PubMed/NCBI
|
12
|
Aggarwal BB, Vijayalekshmi RV and Sung B:
Targeting inflammatory pathways for prevention and therapy of
cancer: short-term friend, long-term foe. Clin Cancer Res.
15:425–430. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Babbar N and Gerner EW: Targeting
polyamines and inflammation for cancer prevention. Recent Results
Cancer Res. 188:49–64. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Demaria S, Pikarsky E, Karin M, Coussens
LM, et al: Cancer and inflammation: promise for biologic therapy. J
Immunother. 33:335–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Greenwald RJ, Freeman GJ and Sharpe AH:
The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Nakanishi J, Wada Y, Matsumoto K, et al:
Overexpression of B7-H1 (PD-L1) significantly associates with tumor
grade and postoperative prognosis in human urothelial cancers.
Cancer Immunol Immunother. 56:1173–1182. 2007. View Article : Google Scholar : PubMed/NCBI
|
17
|
Sun J, Xu K, Wu C, et al: PD-L1 expression
analysis in gastric carcinoma tissue and blocking of
tumor-associated PD-L1 signaling by two functional monoclonal
antibodies. Tissue Antigens. 69:19–27. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Ghebeh H, Mohammed S, Al-Omair A, et al:
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in
breast cancer patients with infiltrating ductal carcinoma:
correlation with important high-risk prognostic factors. Neoplasia.
8:190–198. 2006. View Article : Google Scholar
|
19
|
Fife BT, Pauken KE, Eagar TN, et al:
Interactions between PD-1 and PD-L1 promote tolerance by blocking
the TCR-induced stop signal. Nat Immunol. 10:1185–1192. 2009.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Blank C, Gajewski TF and Mackensen A:
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T
cells as a mechanism of immune evasion: implications for tumor
immunotherapy. Cancer Immunol Immunother. 54:307–314. 2005.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Blank C, Kuball J, Voelkl S, Wiendl H, et
al: Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell
responses in vitro. Int J Cancer. 119:317–327. 2006. View Article : Google Scholar : PubMed/NCBI
|
22
|
Blank C and Mackensen A: Contribution of
the PD-L1/PD-1 pathway to T-cell exhaustion: an update on
implications for chronic infections and tumor evasion. Cancer
Immunol Immunother. 56:739–745. 2007. View Article : Google Scholar : PubMed/NCBI
|
23
|
Karwacz K, Arce F, Bricogne C, et al:
PD-L1 co-stimulation, ligand-induced TCR down-modulation and
anti-tumor immunotherapy. Oncoimmunology. 1:86–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Chen J, Feng Y, Lu L, et al:
Interferon-γ-induced PD-L1 surface expression on human oral
squamous carcinoma via PKD2 signal pathway. Immunobiology.
217:385–393. 2012.
|
25
|
Fan J, Nishanian P, Breen EC, McDonald M
and Fahey JL: Cytokine gene expression in normal human lymphocytes
in response to stimulation. Clin Diagn Lab Immunol. 5:335–340.
1998.PubMed/NCBI
|
26
|
Germano G, Allavena P and Mantovani A:
Cytokines as a key component of cancer-related inflammation.
Cytokine. 43:374–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Dranoff G: Immune recognition and tumor
protection. Curr Opin Immunol. 14:161–164. 2002. View Article : Google Scholar
|
28
|
Chow MT, Möller A and Smyth MJ:
Inflammation and immune surveillance in cancer. Semin Cancer Biol.
22:23–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
29
|
Joyce JA and Pollard JW:
Microenvironmental regulation of metastasis. Nat Rev Cancer.
9:239–252. 2009. View
Article : Google Scholar : PubMed/NCBI
|
30
|
Keibel A, Singh V and Sharma MC:
Inflammation, microenvironment, and the immune system in cancer
progression. Curr Pharm Des. 15:1949–1955. 2009. View Article : Google Scholar : PubMed/NCBI
|
31
|
Rauch D, Gross S, Harding J, Bokhari S,
Niewiesk S, et al: T-cell activation promotes tumorigenesis in
inflammation-associated cancer. Retrovirology. 6:1162009.
View Article : Google Scholar : PubMed/NCBI
|
32
|
DeNardo DG and Coussens LM: Inflammation
and breast cancer. Balancing immune response: crosstalk between
adaptive and innate immune cells during breast cancer progression.
Breast Cancer Res. 9:2122007. View Article : Google Scholar : PubMed/NCBI
|